We evaluated the effects of intravenous and long-term oral sotalol treatment in 17 patients with an accessory atrioventricular (AV) pathway. All patients had a history of symptomatic supraventricular tachycardia. During electrophysiologic study intravenous (1.5 mg/kg body weight) and oral (240 to 320 mg/day) sotalol caused significant increases of sinus cycle length, AV nodal conduction time, and refractory periods of atrial and ventricular myocardium and accessory pathway. AV reciprocating tachycardia, which was inducible and sustained in 15 patients at control, was still inducible after intravenous sotalol in 14 patients, including one in whom it was not inducible at control. However, tachycardia became nonsustained in 10 patients. In seven patients who underwent repeat drug testing while on oral sotalol, results were the same as after intravenous sotalol. Sixteen patients were followed-up for 36 months (median value). Fifteen of them were clinically free of symptoms or experienced marked improvement, despite recurrences of tachycardia in two. In a third patient sotalol had to be withdrawn because of recurrent supraventricular tachycardia. Orthostatic hypotension occurred in five patients and required withdrawal of sotalol in one. To predict the long-term clinical outcome of patients, exercise testing and Holter monitoring were of little or no value. Programmed electrical stimulation predicted clinical outcome in 63% after intravenous and in 86% after oral sotalol. This study shows that long-term treatment with sotalol is highly effective in patients with the Wolff-Parkinson-White syndrome and regular supraventricular tachycardia.
SOTALOL is a ,3-blocking agent without cardioselectivity, intrinsic sympathomimetic, or membrane-stabilizing effects. In addition to its class II antiarrhythmic properties, it prolongs action potential duration and increases atrial as well as ventricular effective refractory periods. This has initially been shown in animal preparations,1 2 and later on in electrophysiologic studies in humans. 3 The additional class III mode of antiarrhythmic action' gave rise to the investigation of the effects of sotalol on supraventricular and ventricular tachyarrhythmias.>12
The aims of our study were to assess (1) the electrophysiologic effects of intravenous and oral sotalol in patients with an accessory atrioventricular pathway and recurrent paroxysmal supraventricular tachycardia, (2) the clinical effects of a long-term treatment with oral sotalol, and (3) the value of exercise testing, Holter monitoring, and programmed electrical stimulation for prediction of the clinical outcome of patients receiving oral sotalol therapy.
Methods
Patients. Seventeen nonselected patients (nine men and eight women; mean age 32 + 12 years) with an accessory atrioventricular pathway and symptomatic supraventricular tachycardia were studied. Clinical data are listed in table 1. In the majority of patients several antiarrhythmic drugs had failed to prevent supraventricular tachycardia. One patient (No. 11) had Ebstein's anomaly, but the other patients showed no signs of an organic heart disease. The baseline evaluation included 12-lead electrocardiographic examinations at rest and during supine bicycle exercise, 24 hr Holter monitoring, two-dimensional echocardiography, and electrophysiologic study off drugs.
Electrocardiographic studies. Analysis of the electrocardiograms recorded in patients at rest consisted of measurement of sinus cycle length, PQ (P-delta) interval, QRS width, and QT interval. Corrected QT interval (QTc) was calculated according to Bazett's formula. 13 The PQ interval was defined as the interval from onset of the P wave to onset of the QRS complex, and the QT interval was defined as the interval from the onset of the QRS complex to the end of the T wave.
Holter monitoring. The written consent and were studied in the nonsedated, postabsorptive state. They had been off any cardioactive medication for at least 72 hr before the study. The electrophysiologic investigation was performed as previously described. '4 In each patient, four electrode catheters were introduced percutaneously via both femoral veins and positioned in the lateral high right atrium, coronary sinus, area of the His bundle, and right ventricular apex, to record intracardiac electrograms. Decremental stimulation with the use of extrastimulus testing and pacing at increasing rates was performed at the high right atrium, coronary sinus, and right ventricular apex. Refractory periods were determined according to standard criteria.' The antegrade effective refractory period of the accessory pathway, defined as the longest A1A2 interval that failed to maintain conduction via the accessory pathway, was determined by stimulating the atrial insertion of the accessory pathway at increasing rates. The retrograde effective refractory period of the accessory pathway was measured during right ventricular stimulation at increasing rates. Atrial fibrillation was not induced in our patients systematically to avoid repetitive cardioversions.
Stimulation was performed with an ERA-S-HIS stimulator (Biotronik GmbH, Berlin, F.R.G.) that emits square-wave pulses of 0.5 msec duration at twice diastolic threshold. Five surface electrocardiographic leads and at least four endocardial leads were registered simultaneously at a paper speed of 100 mm/sec on a 16-channel recorder (Siemens Mingograph).
After the baseline study, measurements were repeated 10 to 15 min after intravenous administration of 1.5 mg/kg of sotalol, given within 15 min. Seven patients were also studied electrophysiologically after 3 to 4 weeks of oral treatment with sotalol at a dose of 160 to 320 mg/day. Reciprocating atrioventricular tachycardia was termed sustained if it did not terminate spontaneously within 30 sec.
Follow-up. Of the 17 patients, one (No. 5) was not started on oral sotalol therapy. The remaining 16 patients were followedup for between 1 and 43 months (median 36 months). Clinical history, physical examination, 12-lead electrocardiography at rest and at exercise, and results of 24 hr Holter monitoring were obtained in each patient every 6 months. Follow-up data refer to those collected at the last visit of each patient. End points. A positive response to sotalol was defined as follows:
Clinical symptomatology: less symptoms or none at all. Exercise testing: reduction or abolition of exercise-induced arrhythmias (sustained supraventricular tachycardia in particular).
Holter monitoring: reduction or abolition of spontaneous arrhythimias (sustained supraventricular tachycardia in particular). Programmed electrical stimulation: sustained supraventricular tachycardia no longer inducible ("complete" response) or conversion of sustained to nonsustained type ("partial" response). 16 Furthermore, we determined the value of the different diagnostic methods for prediction of the clinical efficacy of sotalol therapy. Findings in patients were defined as follows: truly positive, if a positive sotalol response detected by the method ("method responder") corresponded with lessening or disappearance of clinical symptoms ("clinical responder"); truly negative, if a "method nonresponder" was a "clinical nonresponder"; falsely positive, if a method responder was a clinical nonresponder; and falsely negative, if a method nonresponder was a clinical responder.
Statistics. Statistical significance of the difference of values before and during treatment was determined by Student's t test for paired data or by Wilcoxon's signed-rank test. A probability value of less than 5% was considered indicative of a statistically significant difference. Vol. 75, No. 5, May 1987 C  IV  0  FU  C  IV  0  FU  C  IV  0  FU  C  IV  0  FU   1  850  860  1030  110  120  100  100  100  120  425  440  440  2  660 760  780  780  85  90  85  90  140  150  120  140  380  440  450  450  3  640 900  850  830  130  150  160  160  80  80  80  80  370  440  480  450  4  680  800  820  120  120   -120  110  120   -115  410 440   -380  5  1000 1150  120  120  150  130  400 440   -6  730  760  770  900  125  135  135  150  120  100  110  100  395  370  390  390  7  660  720  820  700  100  120  105  105  125  130  120  130  370  400  425 With the exception of patients 1, 5, and 14, longterm electrocardiographic monitoring was performed in all patients. Less than 10 atrial premature beats per hour were recorded in three patients (Nos. 8, 9, and 1 1), and less than 30 ventricular premature beats were noted in three other patients (Nos. 3, 10, and 17). Two patients (Nos. 15 and 16) had sustained supraventricular tachycardia. sotalol; 0 = oral sotalol; SCL = sinus cycle length.
Electrophysiology. Table 3 summarizes basic electrophysiologic data. Except for patients 3, 6, 13, and 15, who had concealed accessory pathways, all patients had bidirectionally conducting pathways.
Atrioventricular reciprocating tachycardia (table 4) . Sustained atrioventricular reciprocating tachycardia was inducible in 15 patients. In patients 11 and 16 tachycardia was not inducible. Tachycardia was always of the orthodromic type, with antegrade conduction across the atrioventricular node and retrograde conduction across the accessory pathway.
Response to sotalol Exercise testing. As during control, no arrhythmias were induced by exercise testing in patients on oral sotalol.
Electrocardiography (table 2) . Sinus cycle length increased significantly after intravenous and after oral sotalol. The PQ interval was significantly lengthened only by intravenous sotalol. This increase, however, was only found in patients without preexcitation and was maintained in this group after oral sotalol. QRS width and the QTc interval were not influenced by either form of sotalol therapy. With the exception of patients with a concealed accessory pathway, preexcited QRS complexes were found in all patients during follow-up. Results of Holter monitoring were unremarkable in all patients in whom they were unremarkable before sotalol. Of the eight patients with arrhythmias at control, Holter electrocardiograms remained unchanged in four, revealed a reduced incidence of arrhythmias in three, and revealed nonsustained supraventricular tachycardia in one patient (No. 1 1) who had only atrial premature beats previously (table 5).
Electrophysiology. Intravenous and oral sotalol caused a significant increase in the AH interval, whereas the HV interval remained unchanged. The effective refractory periods of right atrium, right ventricle, and accessory pathway in both an antegrade and retrograde direction increased significantly after sotalol. Because the antegrade effective refractory period of the accessory pathway was shorter than that of the atrioventricular node in all but three patients, no data are given. Conduction block in the accessory pathway in either an antegrade or retrograde direction was not observed in patients on sotalol (table 3) . Atrioventricular reciprocating tachycardia. After intravenous sotalol, tachycardia was inducible in 14 patients, including patient 11, in whom tachycardia could not be induced before administration of drug. Tachycardia was sustained in only four patients (Nos. 7, 11, 12, and 14) . Nonsustained tachycardia in the remaining 10 patients terminated with conduction block in the atrioventricular node (Nos. 5, 8, and 9); in the accessory Vol. 75, No. 5, May 1987 pathway (Nos. 1, 3, and 4); in either the atrioventricular node or the accessory pathway (No. 17); in either the atrioventricular node or the His-Purkinje system (Nos. 2 and 6); or in either the atrioventricular node, the accessory pathway, or the His-Purkinje system (No. 13). In all 14 patients tachycardia cycle length was significantly longer than at the control study, due to a significant increase in atrioventricular nodal and ventriculoatrial conduction times (table 4) .
During oral sotalol therapy, atrioventricular reciprocating tachycardia could be induced in six of seven patients. It was sustained in patient 7 and nonsustained in the other five patients. In all six patients the same response to sotalol had been found after intravenous administration of drug. Tachycardia cycle length had significantly increased due to a significant prolongation of both atrioventricular nodal and ventriculoatrial conduction time. In patient 2 tachycardia was no longer inducible during oral therapy with sotalol.
Clinical follow-up (table 5) . For a median follow-up period of 36 months 16 patients received oral sotalol at a dose ranging from 160 to 320 mg/day (mean 291 ± 60).
Nine of these patients were free of symptoms, and no arrhythmias were documented, but in patient 4 sotalol was withdrawn after 1 month because of intolerable postural hypotension.
Six patients had a lessening of symptoms but still experienced episodes of palpitations. With the exception of patient 1 1, a reduced or unchanged incidence of arrhythmias was found in all of them during long-term electrocardiography. However, recurrences of sustained supraventricular tachycardia were documented by 12-lead electrocardiography in two of these patients (Nos. 3 and 9). In patient 3 tachycardia recurred only during her menstrual period and could always be terminated by an additional dose of 50 mg of ajmaline. She remained on sotalol therapy, because before it was instituted she had had up to four episodes of sustained supraventricular tachycardia per week that were unresponsive to prior antiarrhythmic medication. A single episode of sustained tachycardia 8 months after initiation of sotalol therapy occurred in patient 9 while he was performing heavy exercise. Since this patient had been free of symptoms for 8 months and did not experience another episode of tachycardia, he remained on oral sotalol treatment.
One patient (No. 15) suffered from recurrent daily episodes of documented sustained tachycardia, even after an increase of the dosage to 480 mg/day. Sotalol therapy was stopped in this patient after 2 months.
Only one patient (No. 5) did not receive oral sotalol. C  IV  0  C  IV  0  C  IV  0  C  IV  0   1  Left posterolateral  65  85  10  10  190  260  250  340  2  Right lateral  45  75  90  -35 -30 -30  190  190  330  240  270  300  3  Left lateral  55  70  70  45  45  45  190  240  250  4 Left therapy. Sensitivity, specificity, and predictive accuracy of programmed electrical stimulation in 15 patients who received intravenous sotalol were 71%, 0, and 63%, respectively. In seven patients on oral sotalol, sensitivity and predictive accuracy were both 86%. Specificity for tests of oral sotalol could not be judged because there were no true-negative or false-positive results. Side effects. Postural hypotension was observed in five patients.
Discussion
Sotalol has been shown to be effective, safe, and well tolerated in patients with a variety of supraventricular and ventricular arrhythmias. 2 Its shortand long-term clinical effects have not been studied in a larger series of symptomatic patients with accessory atrioventricular pathways.
Our results demonstrate that intravenous as well as oral sotalol is highly effective in the treatment of patients with an accessory atrioventricular pathway and paroxysmal supraventricular tachycardia. This beneficial effect was clinically maintained during a longterm follow-up period of 3 years.
Similar clinical results of oral sotalol therapy have 1CIRCULATION 1054 been reported in six patients with the Wolff-Parkinson-White syndrome who were followed up for 6.8 months.8 Conduction times. Sotalol prolonged atrioventricular TABLE 4 nodal conduction time as well as ventriculoatrial conduction time via the accessory pathway, not only during sinus rhythm or programmed stimulation but also during tachycardia. Predominant accessory pathway conduction prevented analysis of the effects of sotalol on the His-Purkinje system during sinus rhythm or programmed stimulation. However, during tachycardia, subnodal conduction time was not increased in any patient. In patients with a concealed accessory pathway sotalol did not change subnodal conduction time significantly during sinus rhythm, which is in accordance with previous studies.7 Refractoriness. The effective refractory periods of myocardial tissue and accessory pathway were significantly increased by intravenous sotalol, as found by others.'7 Complete conduction block in the accessory pathway in either direction was never observed. In contrast to the effects of other antiarrhythmic drugs, prolongation of the antegrade effective refractory period of the accessory pathway after sotalol was independent of the control value. 7 This is of special importance in patients with a short antegrade refractory period who are at risk for sudden death due to atrial fibrillation that might deteriorate into ventricular fibrillation. 17, 18 Atrioventricular reciprocating tachycardia. The incidence of the inducibility of sustained atrioventricular Grading of response to PES: complete = SVT no longer inducible; partial = inducible SVT no longer sustained, but nonsustained; no = sustained SVT still inducible; adverse = SVT not inducible at control, but sustained SVT inducible after iv sotalol; NI = SVT not inducible during control or after iv sotalol. reciprocating tachycardia decreased from 88% to 24% after intravenous sotalol. In the majority of patients atrioventricular reciprocating tachycardia became nonsustained or noninducible. Spontaneous termination occurred most frequently in the atrioventricular node, indicating a marked prolongation of its antegrade effective refractory period. Occasionally, tachycardia terminated in the accessory pathway or, as previously reported,5 in the subnodal conduction system, suggesting increased refractoriness within these parts of the reentry circuit. In patients without preexcitation sotalol has been reported to increase the relative refractory period of the His-Purkinje system.M ode of antiarrhythmic action. The electrophysiologic effects of sotalol demonstrated in this study reflect a combined class II and class III mode of action.
Experimental and clinical findings on class II drugs
have demonstrated that they induce an increase in sinus cycle length and atrioventricular nodal conduction time 212 without a consistent prolongation of myocardial refractoriness.2"<7 It has been shown that they fail 1056 to prolong effective refractory periods of the accessory pathway and have no significant effect on the inducibility of atrioventricular reciprocating tachycardia. 28 However, due to impaired atrioventricular conduction, tachycardia was observed to have a significantly longer cycle length and to become nonsustained in 50% of patients . 28 29 Class III drugs have been shown to significantly prolong the effective refractory periods of myocardium and of the accessory pathway in both an antegrade and retrograde direction. 30 31 In the majority of patients studied, sustained atrioventricular reciprocating tachycardia became noninducible during treatment with high oral doses of amiodarone.3`However, amiodarone causes serious side effects in patients on oral long-term treatment, particularly at a high dose. 32 Thus, the sotalol-mediated increases in conduction time and refractoriness of the atrioventricular node appear to reflect its class II antiarrhythmic action, enhanced by the additional class III effect, whereas prolongation of refractoriness of myocardial tissue and the accessory pathway mainly express its class III mode of action.
Prediction of clinical outcome. Different diagnostic techniques are necessary for a complete evaluation of patients with supraventricular tachycardia. The value of these techniques for prediction of the clinical response to long-term antiarrhythmic therapy has not been assessed until now. In this study drug testing was performed prospectively by bicycle exercise, Holter monitoring, and programmed electrical stimulation, so that we were able to determine the value of each technique for the prediction of clinical outcome. Since arrhythmias were never or rarely detected by exercise testing and Holter monitoring, these techniques were of no use in this respect. Programmed electrical stimulation predicted clinical outcome in 63% of patients after intravenous and in 86% of patients after oral sotalol. In all patients who underwent oral drug testing results were predicted by tests conducted during intravenous drug therapy. Because of the extremely favorable clinical outcome in our patients receiving sotalol, in this study no drug testing by any technique would have been necessary.
Side effects. In agreement with previous reports on oral sotalol therapy,5 8,10 serious side effects or the occurrence of drug-induced tachyarrhythmias33 was not observed. Clinical implication. The clinical efficacy and the low incidence of side effects makes sotalol a drug of first choice for patients with the Wolff-Parkinson-White syndrome and episodes of regular supraventricular CIRCULATION tachycardia. Even patients whose arrhythmias are refractory to conventional antiarrhythmic drugs should be given sotalol before amiodarone is considered. To predict the clinical outcome of patients, exercise testing, Holter monitoring, or programmed electrical stimulation may not be necessary. The effect of sotalol in patients with Wolff-Parkinson-White syndrome and documented atrial fibrillation has yet to be established.
